Literature DB >> 11798982

Behçet's disease: immunopathologic and therapeutic aspects.

Robert Meador1, George Ehrlich, Joan M Von Feldt.   

Abstract

Behçet's disease (BD) is a systemic inflammatory disease of unknown etiology. The disease is strongly associated with the human leukocyte antigen (HLA) B51. BD has a chronic course with periodic exacerbations and progressive deterioration. There are no specific diagnostic laboratory tests, although recurrent oral ulceration is an obligatory manifestation for diagnosis. The treatment, which includes local, systemic, or surgical therapies, is based on the severity of the illness; the most appropriate management requires a multidisciplinary approach. This paper summarizes all aspects of BD with particular emphasis on the latest immunologic and treatment aspects.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11798982     DOI: 10.1007/s11926-002-0023-z

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  44 in total

1.  Localization of the pathogenic gene of Behçet's disease by microsatellite analysis of three different populations.

Authors:  N Mizuki; M Ota; K Yabuki; Y Katsuyama; H Ando; G D Palimeris; E Kaklamani; M Accorinti; P Pivetti-Pezzi; S Ohno; H Inoko
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-11       Impact factor: 4.799

Review 2.  Drug therapy in Behçet's disease.

Authors:  A A Okada
Journal:  Ocul Immunol Inflamm       Date:  2000-06       Impact factor: 3.070

3.  Clinical differentiation of oral ulceration in Behçet's disease.

Authors:  D M Main; M A Chamberlain
Journal:  Br J Rheumatol       Date:  1992-11

Review 4.  Common inflammatory diseases of the mouth.

Authors:  R J Conklin; B Blasberg
Journal:  Int J Dermatol       Date:  1991-05       Impact factor: 2.736

5.  Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease.

Authors:  K Masuda; A Nakajima; A Urayama; K Nakae; M Kogure; G Inaba
Journal:  Lancet       Date:  1989-05-20       Impact factor: 79.321

6.  The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behçet's disease. A randomized clinical trial.

Authors:  M Calgüneri; S Kiraz; I Ertenli; M Benekli; Y Karaarslan; I Celik
Journal:  Arthritis Rheum       Date:  1996-12

Review 7.  Novel approaches to Behçet's disease.

Authors:  T Sakane; M Takeno
Journal:  Expert Opin Investig Drugs       Date:  2000-09       Impact factor: 6.206

8.  Evaluation and therapeutic approaches of voiding and erectile dysfunction in neurological Behçet's syndrome.

Authors:  T Erdoğru; T Koçak; P Serdaroğlu; A Kadioğlu; S Tellaloğlu
Journal:  J Urol       Date:  1999-07       Impact factor: 7.450

9.  Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behçet's disease: a randomised trial.

Authors:  H Demiroglu; O I Ozcebe; I Barista; S Dündar; B Eldem
Journal:  Lancet       Date:  2000-02-19       Impact factor: 79.321

10.  Mouth and genital ulcers with inflamed cartilage: MAGIC syndrome. Five patients with features of relapsing polychondritis and Behçet's disease.

Authors:  G S Firestein; H E Gruber; M H Weisman; N J Zvaifler; J Barber; J D O'Duffy
Journal:  Am J Med       Date:  1985-07       Impact factor: 4.965

View more
  2 in total

1.  The prevalence and clinical characteristics of esophageal involvement in patients with Behçet's disease: a single center experience in Korea.

Authors:  Seung Woo Yi; Jae Hee Cheon; Jie Hyun Kim; Sang Kil Lee; Tae Il Kim; Yong Chan Lee; Won Ho Kim
Journal:  J Korean Med Sci       Date:  2009-02-28       Impact factor: 2.153

2.  Associations of HLA-A, -B and -DRB1 types with oral diseases in Swiss adults.

Authors:  Matti Mauramo; Adrian Markus Ramseier; Andreas Buser; Jean-Marie Tiercy; Roland Weiger; Tuomas Waltimo
Journal:  PLoS One       Date:  2014-07-29       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.